<DOC>
	<DOCNO>NCT00001212</DOCNO>
	<brief_summary>Studies show 26 % patient systemic lupus erythematoses nephritis may suffer membranous lupus nephropathy . The disease characterize high level protein urine may eventually lead kidney failure . This study evaluate effectiveness toxic effect immunosuppressive drug therapy patient membranous lupus nephropathy 12 month period . The major goal therapy decrease protein loss ultimately prevent kidney failure . Patients enrol study undergo routine history physical examination . In addition , several diagnostic test conduct include ; chest x-ray ECG , blood urine laboratory test . Patients divide grouped accord severity disease show kidney function . Each group randomly subcategorized different treatment plan . Each treatment plan make immunosuppressive medication include prednisone , cyclophosphamide , cyclosporin A , combination drug . Patients receive medication direct study . The study last 12 month require patient admit two five day study begin study complete . Patients follow outpatient throughout 12 month study .</brief_summary>
	<brief_title>Drug Therapy Lupus Nephropathy</brief_title>
	<detailed_description>This phase 2 trial evaluate effectiveness toxicity immunosuppressive drug therapy patient membranous lupus nephropathy 12 month study period . Patients renal biopsy document membranous nephropathy treated alternate day prednisone randomize receive : ) additional therapy ( control group ) , b ) intravenous cyclophosphamide 1.0 gm per ( 2 ) body surface area every month 6 total dos , c ) oral cyclosporin A 200 mg per ( 2 ) body surface area daily total 11 month . Patients glomerular filtration rate 25-66 ml/min randomize prednisone alone prednisone plus cyclophosphamide . Renal function disease activity monitor throughout study ; physiologic measure glomerular function ( GFR , permselectivity ) examine study entry conclusion study . Comparison make number favorable outcome glomerular function well drug related toxicity achieve treatment group end 12th study month .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>INCLUSION CRITERIA All patient admit study must satisfy follow criterion : Ability provide inform consent aspect study full information provide . SLE define presence least 4 criterion establish American Rheumatism Association . Age 12 year old . Membranous lupus nephropathy manifest 2 gram per day proteinuria absence infection recognize nonlupus renal disease . A renal biopsy must reveal typical membranous lupus nephropathy light microscopy . Immune deposit must predominately subepithelial and/or intramembranous location electron microscopy . EXCLUSION CRITERIA Patients one follow condition exclude : Medication history : cytotoxic drug cyclosporin A 2 week 10 week period prior study entry . cytotoxic drug therapy cyclosporin A 10 week anytime past . cytotoxic drug therapy cyclosporin A 30 day period prior study entry . requirement corticosteroid dose great 20 mg/m ( 2 ) /day prednisone ( equivalent ) control extrarenal disease time study entry . Active acute chronic infection require antimicrobial therapy , serious viral infection ( eg . hepatitis , herpes zoster ) . Pregnant female , nurse mother , female practice birth control . Patients single function kidney . Preexistent malignancy . Insulintreated diabetes mellitus . GFR le 25 ml/min/1.73m ( 2 ) BSA . Known toxicity cyclophosphamide . Positive test HIV infection . Furthermore , patient one follow condition ( relate use cyclosporin A ) exclude randomization within renal function group 2 ( Glomerular filtration rate great 66 ml/min/1.73m ( 2 ) ) : Renal biopsy reveal global sclerosis great 50 percent glomerulus , severe tubular atrophy , severe interstitial fibrosis . Persistently abnormal unexplained liver function abnormality ( define elevate transaminase , bilirubin , alkaline phosphatase twice upper limit normal least 1 month ) evidence active viral hepatitis . Hypertension difficult control uncontrollable conventional antihypertensive regimen . Documented coronary artery disease . Convulsive disorder .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Nephrotic Syndrome</keyword>
	<keyword>Immunosuppressive Drugs</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Cyclosporin A</keyword>
</DOC>